ClinVar Miner

Submissions for variant NM_000138.4(FBN1):c.5699G>A (p.Cys1900Tyr) (rs794728237)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Center for Medical Genetics Ghent,University of Ghent RCV000663808 SCV000787160 pathogenic Marfan syndrome 2017-11-07 no assertion criteria provided clinical testing
GeneDx RCV000181547 SCV000233850 pathogenic not provided 2014-08-14 criteria provided, single submitter clinical testing p.Cys1900Tyr (TGT>TAT): c.5699 G>A in exon 47 of the FBN1 gene (NM_000138.4)The C1900Y mutation in the FBN1 gene has been reported in association with Marfan syndrome (Baetens M et al., 2011; Arbustini E et al., 2005; Attanasio M et al., 2008). Attanasio et al. (2008) reported one individual who met the Ghent criteria for Marfan syndrome, whose features included: pectus carinatum, pes planus, positive wrist and thumb sign, dilation of the ascending aorta, MVP, ectopia lentis and striae. Arbustini et al. (2005) described two patients with C1900Y who met the Ghent criteria for Marfan syndrome. Patient one had aortic root dilation, MVP, ectopia lentis and skeletal findings. Patient two had dural ectasia, skin, eye and skeletal findings without major cardiac findings. C1900Y results in a non-conservative amino acid substitution of Cysteine at a position that is conserved across species. Other mutations affecting the same residue (C1900F, C1900S) and mutations affecting nearby residues (C1895R, C1895Y, G1903Y, G1903R, C1905R) have been reported in association with Marfan syndrome, further supporting the functional importance of this region of the protein. Furthermore, the C1900Y mutation was not observed inapproximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations.In summary, C1900Y in the FBN1 gene is interpreted as a disease-causing mutation. The variant is found in TAAD panel(s).
Invitae RCV000556126 SCV000627939 likely pathogenic Marfan syndrome; Thoracic aortic aneurysm and aortic dissection 2017-08-11 criteria provided, single submitter clinical testing This sequence change replaces cysteine with tyrosine at codon 1900 of the FBN1 protein (p.Cys1900Tyr). The cysteine residue is highly conserved and there is a large physicochemical difference between cysteine and tyrosine. This variant is not present in population databases (ExAC no frequency). This variant has been reported in individuals affected with Marfan syndrome, including an individuals, where the variant was found to arise de-novo (PMID: 16222657, 21542060, 22772377, 18435798 ). ClinVar contains an entry for this variant (Variation ID: 200066). Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.